Table 3. . Nanostructured lipid carriers fabricated using high pressure homogenization technique.
Active ingredient | Solid lipid | Liquid lipid | Surfactants | Size (nm) | Research highlights | Ref. |
---|---|---|---|---|---|---|
Bicalutamide |
Precirol® ATO5 |
Triacetin |
Phosal® 53 MCT, Pluronic® F-127, sodium taurocholate |
130 ± 4.8 to 240 ± 4.1 |
Precirol® ATO 5 and Triacetin were found to be suitable lipids High entrapment efficiency was achieved |
[27] |
Carvedilol |
Glyceryl mono stearate |
Oleic acid |
Poloxamer 188, Tween 80 |
110 |
Desired particle size and percent entrapment efficiency were obtained for enhancement of oral bioavailability |
[28] |
Lovastatin |
Precirol® ATO 5 |
Squalene |
Myversol 18–04 K |
278 ± 2.6 |
Pharmacokinetic parameters were improved after incorporation in NLCs |
[19] |
Luteolin |
Precirol® ATO 5 |
Labrasol® |
Cremophor ELP |
43.89 ± 4.5 |
Luteolin's oral bioavailability improved after encapsulation in NLCs |
[29] |
Mitotane |
Stearic acid |
Triacyl glycerol |
Tween 80, Span 85 |
250 |
NLCs can be successfully provided with positive charge for better mucosal adhesion |
[30] |
Oridonin |
Glycerin monostearate |
Medium chain triglyceride |
Soyabean lecithin S100, poloxamer 188 |
144.9 |
Performance of Biotin-modified oridonin-loaded NLCs in bioavailability was significantly higher in comparison to nonmodified NLCs |
[31] |
Quercetin |
Imwitor 900K |
Medium chain triglyceride |
Tween 80, lecthin, Span 20 |
˜34 to 47 |
Maximum bioaccessbility was observed with NLCs and lipid nanoemulsions compared with SLNs and drug solution |
[32] |
Spironolactone |
Precirol® ATO 5 |
Miglyol 812 |
Tween 80, poloxamer 188 |
150 ± 5 |
Significant improvement in oral bioavailability of drug in comparison to drug syrup High retention of radiolabeled NLCs in intestinal mucosa |
[33] |
Saquinavir |
Precirol® ATO 5 |
Migylol 812 |
Tween 80, poloxamer 188 |
247 |
Hydrophilic P-gp substrate drugs can be effectively delivered through oral route after encapsulation in NLCs |
[34] |
Saquinavir mesylate |
Precirol® ATO 5 |
Migylol 812 |
Tween 80, poloxamer 188 |
244 ± 1 |
Nine-fold increase in saquinavir permeability from Dextran-protamine NLCs in comparison to noncoated NLCs |
[35] |
Testosterone undecanoate |
Dynasan188 |
Oleic acid |
Tween 80 |
200 |
AUC values were found to be doubled in comparison to commercial formulations |
[36] |
Thistle oil, safflower oil, sea buckthorn oil, carrot extract |
Glycerol monostearate |
Cetyl alcohol, beeswax |
Tween 20, phosphatidyl choline |
70–140 |
NLCs demonstrated better antioxidant and anti-inflammatory properties due to synergistic effect of plant-derived oils and extract |
[37] |
Thymoquinone |
Softisan® 154 |
Olive oil |
Polysorbate 80 |
75 ± 2.4 |
Improved gastroprotective effects of drug Pharmacokinetic properties of drug were improved after encapsulation in NLCs |
[38] |
Vinpocetine |
Compritol 888 ATO |
Migylol 812 |
Lecithin solutol HS-15 |
136 ± 4.2 |
Improved oral bioavailability of drug-loaded NLCs (322%) in comparison to drug suspension |
[39] |
Zerumbone | Hydrogenated palm oil | Olive oil, lipoid S100 | Tween 80, thiomerasol | 52.68 ± 0.1 | NLCs showed no acute toxicity at oral doses of 100 and 200 mg/kg | [40] |
AUC: Area under curve; NLC: Nanostructured lipid carrier; SLN: Solid lipid nanoparticle.